Abstract Treatment of hepatocellular carcinoma (HCC) depends on the stage of disease. In
the Western Hemisphere, the Barcelona Clinic Liver Cancer classification (BCLC) is the …

Background The synergy between locoregional therapies and immune checkpoint inhibitors
has not been investigated as conversion therapy for unresectable hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic
hepatitis B is the most common HCC etiology in our region. With the high case load …

Background and Aims NAFLD is the most prevalent chronic liver disease without any Food
and Drug Administration–approved pharmacological intervention in clinic. Fatty acid …

Background: Current treatments of unresectable hepatocellular carcinoma (HCC) are trans-
arterial chemo-embolization (TACE), stereotactic body radiotherapy (SBRT), and targeted …

Conclusions Hypoxia‐induced exosomal miR‐135a‐5p correlates with the development,
clinical severity, and prognosis of CRC liver metastases through the premetastatic niche; …

Purpose A prospective multicenter registry study was started May 2016 in Japan to evaluate
the efficacy and safety of proton beam therapy (PBT) for hepatocellular carcinoma (HCC) …

Simple Summary Hepatocellular carcinoma is the most common type of liver cancer and
affects a significant number of people worldwide. There are multiple treatment options …

Long noncoding RNA, RNA component of mitochondrial RNA processing endoribonuclease
(RMRP) plays an important role in cancer development and is closely correlated with …

The role of ablative stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma
(HCC) has been evolving over the last few decades. SBRT has mostly been used in early …